Avandia Committee Review: FDA Puts Five Options On Table For Advisory Panels
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisors could recommend that GlaxoSmithKline's diabetes drug be taken off the market, that the warnings on its label be downgraded, or a range of in-between options.
You may also be interested in...
IoM Report On Postmarketing Study Ethics Could Drive Broad Overhaul Of Informed Consent
An Institute of Medicine report on ethical and scientific issues in drug safety studies could lead to a broad restructuring of informed consent documents in postmarketing clinical trials
IoM Report On Postmarketing Study Ethics Could Drive Broad Overhaul Of Informed Consent
An Institute of Medicine report on ethical and scientific issues in drug safety studies could lead to a broad restructuring of informed consent documents in postmarketing clinical trials
IoM Report On Postmarketing Study Ethics Could Drive Broad Overhaul Of Informed Consent
Released in advance of Avandia advisory committee meeting, Institute of Medicine report provides a "conceptual framework" for deciding whether safety studies such as TIDE are ethical.